Clinical Trial Update: Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC) [Phase 2]

View source ↗

Summary

The Phase 2 trial of ABT-869 in advanced hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• ABT-869 (linifanib)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Advanced Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED